Page 1506 - Williams Hematology ( PDFDrive )

1480 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1481

472. Cortes JE, Jones D, O’Brien S, et al: Results of dasatinib therapy in patients with early 501. Hughes T, Hochhaus A, Branford S, et al: Long-term prognostic significance of early
chronic-phase chronic myeloid leukemia. J Clin Oncol 28:398, 2010. molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An
473. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diag- analysis from the International Randomized Study of Interferon and STI571 (IRIS).
nosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260, 2010. Blood 116:3758, 2010.
474. Quintás-Cardama A, Choi S, Kantarjian H, et al: Predicting outcomes in patients with 502. Quintas-Cardama A, Kantarjian H, Jones D, et al: Delayed achievement of cytoge-
chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin netic and molecular response is associated with increased risk of progression among
Lymph Myeloma Leuk 14:327, 2014. patients with chronic myeloid leukemia in early chronic phase receiving high-dose of
475. Jabbour E, Kantarjian HM, Saglio G, et al: Early response with dasatinib or imatinib in standard-dose imatinib therapy. Blood 113:6315, 2009.
chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASI- 503. Marin D, Ibrahim AR, Lucas C, et al: Assessment of BCR-ABL1 transcript levels at
SION). Blood 123:494, 2013. 3 months is the only requirement for predicting outcome for patients with chronic
476. Radich JP, Kopecky KJ, Appelbaum FR, et al: A randomized trial of dasatinib 100 mg myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232,
versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. 2012.
Blood 120:3898, 2012. 504. Saglio G, Kantarjian HM, Shah N, et al: Early response (molecular and cytogenetic)
477. Quintas-Cardama A, Han X, Kantarjian H, Cortes J, Tyrosine kinase inhibitor- and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic
induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114: phase (CML-CP): Exploratory analysis of DASISION 3-year data. Blood 12: Abstract
261, 2009. 1675, 2012.
478. Montani D, Bergot E, Gunther S, et al: Pulmonary arterial hypertension in patients 505. Saglio G, Hughes TP, Larson RA, et al: Impact of early molecular response to nilotinib
treated by dasatinib. Circulation 125:2128, 2012. (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts)
479. Ault P: Dasatinib in the first-line treatment of chronic myeloid leukemia. Community with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of
Oncol 9:336, 2012. 4=year (y) data form ENESTnd. J Clin Oncol 31: Abstract 7054, 2013.
480. Schiffer CA, Cortes JE, Saglio G, et al: Lymphocytosis following first-line treatment 506. Marin D, Milojkovic D, Olavarria E, et al: European LeukemiaNet criteria for failure
for CML in chronic phase with dasatinib is associated with improved responses: A or suboptimal response reliably identify patients with CML in early chronic phase
comparison with imatinib. Blood 116: Abstract 358, 2010. treated with imatinib whose eventual outcome is poor. Blood 112:4437, 2008.
481. Kreutzman A, Juvonen V, Karisto V, et al: Mono/oligoclonal T and NK cells are com- 507. O’Dwyer ME, Gatter KM, Loriaux M, et al: Demonstration of Philadelphia chro-
mon in chronic myeloid leukemia patients at diagnosis and expand during dasatinib mosome negative abnormal clones in patients with chronic myelogenous leukemia
therapy. Blood 116:772, 2010. during major cytogenetic responses induced by imatinib mesylate. Leukemia 17:481,
482. Roux C, Nicolini F-E, Rea D, et al: Reversible lymph node follicular hyperplasia asso- 2003.
ciated with dasatinib treatment of chronic myeloid leukemia in chronic phase. Blood 508. Guilbert-Douet N, Morel F, LeBris M-J, et al: Clonal chromosomal abnormalities in
122:3082, 2013. the Philadelphia chromosome negative cells of chronic myeloid leukemia patients
483. Weisberg E, Manley P, Mestan J, et al: AMN107 (nilotinib): A novel and selective treated with imatinib. Leukemia 18:1140, 2004.
inhibitor of BCR-ABL. Br J Cancer 94:1765, 2006. 509. Deininger MW: Cytogenetic studies in patients on imatinib. Semin Hematol 40:50,
484. Jørgensen HG, Allan EK, Jordanides NE, et al: Nilotinib exerts equipotent antiprolif- 2003.
erative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 510. Bumm T, Muller C, Al-Ali K, et al: Emergence of clonal cytogenetic abnormalities in
109:4016, 2007. Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of
485. Rosti G, Palandri F, Castagnetti F, et al: Nilotinib for the frontline treatment of Ph+_ polyclonal hematopoiesis in the majority. Blood 101:1941, 2003.
chronic myeloid leukemia. Blood 114:4933, 2009. 511. Goldberg SL, Medan RA, Rowley SD, et al: Myelodysplastic subclones in chronic mye-
486. Cortes JE, Jones D, O’Brien S, et al: Nilotinib as front-line treatment for patients with loid leukemia: Implications for imatinib mesylate therapy. Blood 101:781, 2003.
chronic myeloid leukemia in early chronic phase. J Clin Oncol 28:392, 2009. 512. Farag SS, Ruppert AS, Mrozek K, et al: Prognostic significance of additional cyto-
487. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed genetic abnormalities in newly diagnosed patients with Philadelphia chromosome-
chronic myeloid leukemia. N Engl J Med 362:2251, 2010. positive chronic myelogenous leukemia treated with interferon-alpha: A Cancer and
488. Larson RA, Hochhaus A, Hughes TP, et al: Nilotinib vs imatinib in patients with newly Leukemia Group B study. Int J Oncol 25:143, 2004.
diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic 513. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, et al: Clonal Ph-negative hemato-
phase: ENESTnd 3-year follow-up. Leukemia 26:2197, 2012. poiesis in CML after therapy with imatinib mesylate is frequently characterized by
489. Hochhuas A, Saglio G, Larson RA, et al: Nilotinib is associated with a reduced inci- trisomy 8. Leukemia 16:1390, 2002.
dence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic 514. Terre C, Eclache V, Rousselot P, et al: Report of 34 patients with clonal chromo-
myeloid leukemia in chronic phase. Blood 121:3703, 2013. somal abnormalities in Philadelphia-negative cells during imatinib treatment of
490. Giles FJ, Mauro MJ, Hong F, et al: Rates of peripheral arterial occlusive disease in Philadelphia-positive chronic myeloid leukemia. Leukemia 18:1340, 2004.
patients with chronic myeloid leukemia in the chronic phase treated with imatinib, 515. Jabbour E, Kantarjian HM, Abruzzo LV, et al: Chromosomal abnormalities in Phila-
nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis. Leukemia delphia chromosome negative metaphases appearing during imatinib mesylate ther-
27:1310, 2013. apy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
491. Stenger MS: Bosutinib in previously treated CML and in first-line comparison with Blood 110:2991, 2007.
imatinib. Community Oncol 10:105, 2013. 516. Cortes JE, Talpaz M, Giles F, et al: Prognostic significance of cytogenetic clonal evo-
492. Cortes JE, Kim DW, Kantarjian HM, et al: Bosutinib versus imatinib in newly diag- lution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
nosed chronic-phase chronic myeloid leukemia: Results from the BELA trail. J Clin Blood 101:3794, 2003.
Oncol 30:3486, 2012. 517. Chee YL, Vickers MA, Stevenson D, et al: Fatal myelodysplastic syndrome developing
493. Akard LP, Albitar M, Hill CE, Pinilla-Ibarz J: The “hit hard and hit early” approach during therapy with imatinib mesylate and characterised by the emergence of com-
to the treatment of chronic myeloid leukemia: Implications of the updated national plex Philadelphia negative clones. Leukemia 17:634, 2003.
comprehensive cancer network clinical practice guidelines for routine practice. Clin 518. Noens L, van Lierde MA, De Bock R, et al: Prevalence, determinants, and outcomes
Adv Hematol Oncol 11:421, 2013. of nonadherence ot imatinib therapy in patients with chronic myeloid leukemia: The
494. Goldman JM, Marin D: Is imatinib still an acceptable first-line treatment for CML in ADAGIO study. Blood 113:5401, 2009.
chronic phase? Oncology (Williston Park) 26:901, 2012. 519. Ibrahim AR, Eliasson L, Apperley JF, et al: Poor adherence is the main reason for loss
495. Baccarani M, Deininger MW, Rosli G, et al: European LeukemiaNet recommen- of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term
dations for the management of chronic myeloid leukemia: 2013. Blood 122:872, therapy. Blood 1176:3722, 2011.
2013. 520. Marin D, Bazeos A, Mahon F-X, et al: Adherence is the critical factor for achieving
496. Kantarjian H, Talpaz M, O’Brien S, et al: Prediction of initial cytogenetic response for molecular responses in patients with chronic myeloid leukemia who achieve complete
subsequent major and complete cytogenetic response to imatinib mesylate therapy cytogenetic responses on imatinib. J Clin Oncol 28:2381, 2010.
in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. 521. Hochhaus A, La Rosse P: Imatinib therapy in chronic myelogenous leukemia: Strate-
Cancer 98:1776, 2003. gies to avoid and overcome resistance. Leukemia 18:1320, 2004.
497. Druker BJ, Guilhot F, O’Brien SG, et al: Five-year follow-up of patients receiving ima- 522. Cowan-Jacob SW, Guez V, Fendrich G, et al: Imatinib (STI571) resistance in chronic
tinib for chronic myeloid leukemia. N Engl J Med 355:2408, 2006. myelogenous leukemia: Molecular basis of the underlying mechanism and potential
498. de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed strategies for treatment. Mini Rev Med Chem 4:285, 2004.
patients with chronic myeloid leukemia: Incidence of sustained response in an inten- 523. Melo JV: Resistance to imatinib mesylate in CML: All BCR-ABL mutations “are cre-
tion-to-treat analysis. J Clin Oncol 26:3358, 2008. ated equal but some are more equal than others.” Blood 101:4231, 2003.
499. Jabbour E, Kantarjian H, O’Brien S, et al: The achievement of an early complete cyto- 524. Villuendas R, Steegmann JL, Pollán M, et al: Identification of genes involved in ima-
genetic response is a major determinant for outcome in patients with early chronic tinib resistance in CML: A gene-expression profiling approach. Leukemia 20:1047,
phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2006.
118:4541, 2011. 525. Jiang X, Zhao Y, Forrest D, et al: Stem cell biomarkers in chronic myeloid leukemia.
500. Cortes J, Talpaz M, O’Brien S, et al: Molecular response in patients with chronic mye- Dis Markers 24:201, 2008.
logenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 526. Barnes DJ, Melo JV: Primitive, quiescent and difficult to kill: The role of non-
22:3425, 2005. proliferating stem cells in chronic myeloid leukemia. Cell Cycle 5:2862, 2006.

Kaushansky_chapter 89_p1437-1490.indd 1481 9/18/15 3:42 PM